irsogladine
Trade name: Gaslon N
Small moleculeexperimental
Irsogladine is a phosphodiesterase inhibitor. — Wikipedia
Clinical trial activity
4 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
0
Phase 3
0
Phase 4
1
Earliest trial started Aug 1, 2015 (NCT02581696)
Timeline
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Unspecified targetUnclear
Unclear
Chemistry & pharmacology
Loading structure…
SMILES
Nc1nc(N)nc(-c2cc(Cl)ccc2Cl)n1- Mol. weight
- 256.1 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL136497 ↗
- WikipediaIrsogladine ↗
- ChEMBLCHEMBL1712923 ↗
Also known as
- 2,4-diamino-6-(2,5-dichlorophenyl)-s-triazine maleate
- 6-(2,5-dichlorophenyl)-2,4-diamino-1,3,5-triazine
- dcpdat
- dicloguamine
- irsogladine
- irsogladine
- irsogladine
- irsogladine
- irsogladine
- irsogladine
- irsogladine
- irsogladine
- irsogladine maleate
- irsogladine maleate
- irsogladine maleate
- irsogladine maleate
- mn 1695
- mn-1695
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05249725 | Phase 4 | Apr 30, 2022 | Lee's Pharmaceutical |
| NCT03509831 | Phase 1 | Nov 2, 2017 | Inha University, Kukje Pharma |
| NCT02759224 | Phase 1 | Apr 15, 2016 | Boryung Pharmaceutical Company |
| NCT02581696 | Phase 1 | Aug 1, 2015 | Boryung Pharmaceutical Company, Catholic University of Korea |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Boryung Pharmaceutical Company | For profit | 2 | 2 | 1 | 2015 |
| Catholic University of Korea | Academic/Hospital | 1 | 0 | 1 | 2015 |
| Inha University | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Kukje Pharma | For profit | 1 | 1 | 1 | 2017 |
| Lee's Pharmaceutical | For profit | 1 | 1 | 1 | 2022 |
5 organizations
Page 1 / 1